Figure 2

Effect of EPO on iPS pNPCs. (A) pNPCs express EPOR mRNA and functional EPOR: EPO treatment leads to an increase in ERK1,2 (MAPK) phosphorylation (n = 6, C1; n = 4, C2). (B) Effect of EPO treatment on cell survival after 24 h and 48 h (n = 4 in each group). (C) Effect of EPO on pNPC proliferation (n = 4 in each group). The percentage of fast proliferating cells (cells gated with low CFSE signal in inset) is decreased in both clonal lines after EPO treatment. (D) Effect of EPO on sphere formation under different seeding concentration (n = 4 in each group). (E) The number of TuJ1-positive neurons in cultures treated with placebo or EPO (1 U/mL) (n = 4 in each group). The average number of living cells per field was 19 ± 7 (placebo) and 29 ± 13 (EPO) for d 2, 19 ± 7 (placebo) and 22 ± 11 (EPO) for d 4 and 17 ± 8 (placebo) and 16 ± 5 (EPO) for d 6, respectively. Data represent mean ± SD for the indicated number of samples, *p < 0.05, **p < 0.01 versus placebo, ^#p < 0.05 versus EPO 0.1 U/mL (B) or versus EPO 0.3 U/mL (D); t test for normal and Wilcoxon test for not normal distributed samples.